STAT3/磷酸化STAT3在肿瘤中的预后意义：文献的荟萃分析
Prognostic significance of STAT3/phosphorylated-STAT3 in tumor: a meta-analysis of literatures.
作者信息
Kong Hongyu, Zhang Qiongwen, Zeng Yunhui, Wang Hong, Wu Mengqian, Zheng Tianying, Zeng Yanzhang, Shi Huashan
机构信息
Clinical Medicine (Eight-Year Program), West China School of Medicine, Sichuan University Chengdu, Sichuan, PRC.
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medicine School, Sichuan University Chengdu, Sichuan, PRC ; State Key Laboratory of Biotherapy and Department of Head and Neck Oncology, West China Hospital, West China Medical School, Sichuan University Chengdu, Sichuan, PRC.
出版信息
Int J Clin Exp Med. 2015 Jun 15;8(6):8525-39. eCollection 2015.
PURPOSE
The prognostic value of the expression of STAT3/phosphorylated-STAT3 on survival for cancer patients remains controversial. We performed a meta-analysis of the published literature in this field to identify its impact.
METHODS
We conducted a meta-analysis of 26 studies (n=3877 patients) that evaluated the relationship between the prognostic value and the expression of STAT3/phosphorylated-STAT3 in 15 different kinds of carcinomas. Studies evaluated the correlation between STAT3/phosphorylated-STAT3, which detected mostly by immunohistochemistry and western blot, and clinical staging, overall survival (OS) and disease free survival (DFS) were included. The impact of STAT3 and phosphorylated-STAT3 was analyzed separately.
RESULTS
A total of 26 studies (14 for STAT3 and 16 for phosphorylated-STAT3), comprising 3877 patients, were included for meta-analysis. The expression of STAT3 was strongly associated with a poor impact on overall survival (OS) in all eligible studies [hazard ratio (HR)=2.91, (95% confidence interval (CI), 1.91-4.42)], while a significant association was shown between the expression of phosphorylated-STAT3 and patients' outcome [HR=1.53, (95% CI, 0.86-2.70)]. No significant effect was shown between the expression of STAT3/phosphorylated-STAT3 and clinical staging, neither with DFS.
CONCLUSION
High expression of STAT3 seems to be associated with poor OS in patients with carcinomas, while phosphorylated-STAT3 does not.
目的
信号转导和转录激活因子3（STAT3）/磷酸化信号转导和转录激活因子3（p-STAT3）的表达对癌症患者生存的预后价值仍存在争议。我们对该领域已发表的文献进行了荟萃分析，以确定其影响。
方法
我们对26项研究（n = 3877例患者）进行了荟萃分析，这些研究评估了15种不同类型癌症中STAT3/p-STAT3的表达与预后价值之间的关系。纳入的研究评估了主要通过免疫组织化学和蛋白质印迹法检测的STAT3/p-STAT3与临床分期、总生存期（OS）和无病生存期（DFS）之间的相关性。分别分析了STAT3和p-STAT3的影响。
结果
总共纳入了26项研究（14项关于STAT3，16项关于p-STAT3），共3877例患者进行荟萃分析。在所有符合条件的研究中，STAT3的表达与总体生存（OS）的不良影响密切相关[风险比（HR）= 2.91，（95%置信区间（CI），1.91 - 4.42）]，而p-STAT3的表达与患者预后之间存在显著关联[HR = 1.53，（95% CI，0.86 - 2.70）]。STAT3/p-STAT3的表达与临床分期以及DFS之间均未显示出显著影响。
结论
STAT3的高表达似乎与癌症患者的不良OS相关，而p-STAT3则不然。
Zotero 插件